Sujal Shah is the founder of CymaBay Therapeutics. CymaBay Therapeutics has raised $4.3B in total funding. Latest round: IPO. Backed by Gilead Sciences.
Sujal Shah is a biomedical engineer who transitioned into healthcare investment banking before joining CymaBay Therapeutics. He served as CEO of CymaBay, navigating the company through a significant safety scare and ultimately leading it to a successful acquisition by Gilead Sciences.
Full founder directory · Investor directory · Company funding database · Fundraising library